Table 1.
Studies | Patients randomized to control or intervention group, study duration | App features | Hospitalizations | Quality of life | Notable outcomes | Comments |
Seto et al [22]a | 50/50, 6 months |
|
No difference observed between groups (P=.1) |
|
More patients were prescribed with aldosterone antagonists in the intervention group (P=.02) |
|
Vuorinen et al [23]a | 47/47, 6 months |
|
No difference observed between groups (P=.35) | N/Af |
|
No difference between groups regarding N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction, and other clinical variables |
Hägglund et al [24]g | 40/32, 3 months |
|
2.2 less hospital days per patient due to HF for the intervention group versus control (relative risk 0.38; P<.05) |
|
N/A |
|
Athilingam et al [25]a | 9/9, 1 month |
|
N/A |
|
Significant improvement regarding self-care management (P=.01) and self-care confidence (P=.03) of the intervention group versus the control group, as appraised by the Self-Care of Heart Failure Index |
|
aThe study intervention was smartphone based.
bDenotes functional features (ie, those directly specific to patient self-management).
cDenotes nonfunctional features (ie, those not directly specific to patient self-management features).
dMLHFQ: Minnesota Living with Heart Failure Questionnaire.
eHF: heart failure.
fN/A: not applicable.
gThe study intervention was tablet based.
hKCCQ: Kansas City Cardiomyopathy Questionnaire.
iSF-36: 36-Item Short Form Survey.